Modern Landscape of Innovative Technologies in Optimizing the Quality of Life of Cancer Patients
DOI:
https://doi.org/10.15407/exp-oncology.2024.04.281Keywords:
quality of life, precision medicine, innovative technologies, cancer patientsAbstract
In the era of the intensive development of post-genomic technologies, it is reasonable to review the modern strategy for solving the problems of cancer patients. The current trend of the new paradigm is based on the knowledge and possibilities of correcting molecular genetic processes based on the principles of precision medicine. The key role in implementing such an approach belongs to modern innovative technologies, among which omics technologies occupy a special place. The genesis of the symbiosis of medical-biological and cybernetic technologies aimed at processing information databases becomes the subject of learning the functioning of complex biological systems. Today, for the dynamic development of the implementation of precision medicine based on innovative technologies, it is worth concentrating the efforts on the deep consolidation of transdisciplinary approaches that can form an algorithm of a new market of medical services aimed at improving the quality of life.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mor- tality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. https://doi.org/10.3322/ caac.21660
Fedorenko Z, Sumkina O, Gorokh Ye, et al. Cancer in Ukraine 2022—2023: Incidence, mortality, prevalence and other relevant statistics. Bull Nat Cancer Registry Ukr. 2024;25:132.
Eiriz IF, Vaz Batista M, Cruz Tomás T, et al. Breast cancer in very young women-a multicenter 10-year experience.
ESMO Open. 2021;6(1):100029. https://doi.org/10.1016/j.esmoop.2020.100029
Chekhun V, Martynyuk О, Lukianova Y, et al. Features of breast cancer in patients of young age: search for diagno- sis optimization and personalized treatment. Exp Oncol. 2023;45(2):139-150. https://doi.org/10.15407/exp-oncolo- gy.2023.02.139
Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr Opin Gastroenterol. 2008;24(1):4-10. https://doi.org/10.1097/MOG.0b013e3282f2b0e8
Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59-65. https://doi.org/10.1038/nature08821
Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project. Nature. 2019;569(7758):641-648. https://doi.org/10.1038/s41586-019-1238-8
Shvets YV, Lykhova OO, Chekhun VF. Human microbiota and breast cancer. Exp Oncol. 2022;44(2):95-106. https:// doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17855
Rodriguez Castells M, Baraibar I, Ros J, et al. The impact of clinical and translational research on the quality of life during the metastatic colorectal cancer patient journey. Front Oncol. 2023;13:1272561. https://doi.org/10.3389/ fonc.2023.1272561
Tonorezos ES, Henderson TO. Clinical Guidelines for the Care of Childhood Cancer Survivors. Children (Basel). 2014;1(2):227-240. https://doi.org/10.3390/children1020227
van Leeuwen M, Husson O, Alberti P, et al. Understanding the quality of life (QOL) issues in survivors of can- cer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16(1):114. https://doi.org/10.1186/s12955-018-0920-0
Schütte K, Schulz C, Middelberg-Bisping K. Impact of gastric cancer treatment on quality of life of patients. Best Pract Res Clin Gastroenterol. 2021;50-51:101727. https://doi.org/10.1016/j.bpg.2021.101727
Gour N, Chaudhary M. The quality of life in cancer patients [Internet]. Supportive and palliative care and quality of life in oncology. IntechOpen; 2023. Available from: https://doi.org/10.5772/intechopen.105990
Rizzo M, Tammaro G, Guarino A, et al. Quality of life in osteoporotic patients. Orthop Rev (Pavia). 2022;14(6):38562. https://doi.org/10.52965/001c.38562
Rulten SL, Grose RP, Gatz SA, et al. The future of precision oncology. Int J Mol Sci. 2023;24(16):12613. https://doi. org/10.3390/ijms241612613
Khondakar KR, Anwar MS, Mazumdar H, Kaushik A. Perspective of point-of-care sensing system in cancer manage- ment. Mater Adv. 2023;4:4991-5002. https://doi.org/10.1039/D3MA00525A
Chekhun V.F. From system biology of cancer to methodology of personifi ation treatment. Oncology. 2012;14(2):84-88.
Gadade DD, Jha H, Kumar C, Khan F. Unlocking the power of precision medicine: exploring the role of biomarkers in cancer management. Future J Pharm Sci. 2024;10(1):5. https://doi.org/10.1186/s43094-023-00573-2
Jain K.K. Personalized Medicine. Decision Resources Inc. Waltham, MA, USA, 1998
Pryzimirska TV, Pogribny IP, Chekhun VF. The impact of tumor growth on plasma homocysteine levels and tissue- specific DNA methylation in Walker-256 tumor-bearing rats. Exp Oncol. 2007;29(4):262-266.
Zadvornyi T, Lukianova N, Mushii O, et al. Benign and malignant prostate neoplasms show different spatial organi- zation of collagen. Croat Med J. 2023;64(6):413-420. https://doi.org/10.3325/cmj.2023.64.413.
Chekhun V, Borikun T, Zadvornyi T, et al. Osteonectin (SPARC) prognostic value in prostate cancer. Pathol Res Pract. 2024;254:155053. https://doi.org/10.1016/j.prp.2023.155053
Zadvornyi T, Lukianova N, Borikun T, et al. Mast cells as a tumor microenvironment factor associated with the ag- gressiveness of prostate cancer. Neoplasma. 2022;69(6):1490-1498. https://doi.org/10.4149/neo_2022_221014N1020
Lykhova O, Zavelevich M, Philchenkov A, et al. Does insulin make breast cancer cells resistant to doxorubicin toxic- ity? Naunyn Schmiedebergs Arch Pharmacol. 2023;396(11):3111-3122. https://doi.org/10.1007/s00210-023-02516-3
Chekhun VF, Boroday NV, Yurchenko OV. MicroRNA and tumor process. Oncologia. 2012;15(2):136-140 (in Russian).
Chekhun VF. MicroRNAs are a key factor in the globalization of tumor-host relationships. Exp Oncol. 2019;41(3):188- 194. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13431
Chekhun VF, Lukianova NY, Borikun TV, et al. The expression profile of tissue and circulating miRNAs for optimi- zation of neoadjuvant therapy of breast cancer patients. In Watanabe HS, ed. Horizons in Cancer Research. Vol. 80. Nova Science Publishers, 2021:63-112.
Zadvornyi TV, Lukianova NY, Borikun TV, et al. NANOG as prognostic factor of prostate cancer course. Exp Oncol. 2020;42(2):94-100. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14673
Lukianova N, Zadvornyi T, Kashuba E, et al. Expression of markers of bone tissue remodeling in breast cancer and prostate cancer cells in vitro. Exp Oncol. 2022;44(1):39-46. https://doi.org/10.32471/exp-oncology.2312-8852. vol-44-no-1.17354
Larijani B, Aghaei Meybodi HR, et al. Principles of Precision Medicine. In: Hasanzad, M. (eds) Precision Medicine in Clinical Practice. Springer, Singapore. 2022. https://doi.org/10.1007/978-981-19-5082-7_1
Nair SS, Weil R, Dovey Z, Davis A, et al. The tumor microenvironment and immunotherapy in prostate and bladder cancer. Urol Clin North Am. 2024;47(4):e17-e54. https://doi.org/10.1016/j.ucl.2020.10.005
Ross SA. Nutritional genomic approaches to cancer prevention research. Exp Oncol. 2007;29(4):250-256.
ESMO Handbook of Nutrition and Cancer. Henk van Halteren, Aminah Jatoi, eds. ESMO Press, 2011. 101p.
Martínez-Garay C, Djouder N. Dietary interventions and precision nutrition in cancer therapy. Trends Mol Med. 2023;29(7):489-511. https://doi.org/10.1016/j.molmed.2023.04.004
Chekhun V. Symbiosis of medical technologies and artificial intelligence: new opportunities in oncology. Exp Oncol. 2022;44(2):90-92. https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-2.17951
Lukianova N, Mushii O, Zadvornyi T, Chekhun V. Development of an algorithm for biomedical image analysis of the spatial organization of collagen in breast cancer tissue of patients with different clinical status. FEBS Open Bio. 2024;14(4):675-686. https://doi.org/10.1002/2211-5463.13773
Lukianova N, Zadvornyi T, Mushii О, et al. Evaluation of diagnostic algorithm based on collagen organization parameters for breast tumors. Exp Oncol. 2022;44(4):281-286. https://doi.org/10.32471/exp-oncology.2312-8852. vol-44-no-4.19137.
Naqvi MR, Jaffar MA, Aslam M, et al. Importance of big data in precision and personalized medicine. 2020 Interna- tional Congress on Human-Computer Interaction, Optimization and Robotic Applications (HORA). 2020: 1-6.
Liu X, Jiang H, Wang X. Advances in cancer research: current and future diagnostic and therapeutic strategies.
Biosensors (Basel). 2024;14(2):100. https://doi.org/10.3390/bios14020100
Ozaki Y, Broughton P, Abdollahi H, et al. Integrating Omics data and AI for cancer diagnosis and prognosis. Cancers. 2024;16(13):2448. https://doi.org/10.3390/cancers16132448
Denny JC, Collins FS. Precision medicine in 2030 — seven ways to transform healthcare. Cell. 2021:2021;184(6):1415- 1419. https://doi.org/10.1016/j.cell.2021.01.015
Precision Oncology Market, Global Forecast 2023—2032. 2023. https://www.gminsights.com/industry-analysis/ precision-oncology-market Accessed December, 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
